Nasus Pharma NSRX
NYSE NSRX
$3.90 +0.05 (+1.30%)
As of: Aug 21, 2026 · 1:00 PM EDT

Nasus Pharma (NSRX) Retained Earnings (2024 - 2025)

Nasus Pharma's (NSRX) quarterly Retained Earnings came in at $21.3 million in Q4 2025, up 268.1% YoY from $5.8 million in Q4 2024, and up 122.17% on a QoQ basis from $9.6 million in Q2 2025.

Nasus Pharma (NSRX) Retained Earnings (2024 - 2025) Analysis & Trends

Nasus Pharma (NSRX) has 2 years of Retained Earnings data on file, last reported at $21.3 million in Q4 2025.

  • Quarterly Retained Earnings rose 268.1% year-over-year to $21.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $21.3 million (up 268.1% YoY) and the FY2025 annual result came in at $21.3 million, up 268.1% from the prior year.
  • Retained Earnings climbed to $21.3 million in Q4 2025, from $9.6 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $21.3 million in Q4 2025 to a low of -$12.7 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Retained Earnings (Qtr)
1 Johnson & Johnson 652.29 Bn 631.53 Bn 17.26 Bn 171.67 Bn
2 AbbVie 470.62 Bn 464.06 Bn 12.70 Bn -17.33 Bn
3 Merck 375.66 Bn 368.52 Bn 12.21 Bn 63.27 Bn
4 Novartis Ag 302.90 Bn 295.21 Bn 11.24 Bn -
5 Astrazeneca 257.50 Bn 252.60 Bn 12.86 Bn 12.59 Bn
6 Amgen 237.19 Bn 223.20 Bn 7.24 Bn -22.28 Bn
7 Gilead Sciences 182.92 Bn 179.74 Bn 6.22 Bn 9.53 Bn
8 Pfizer 160.14 Bn 148.44 Bn 10.94 Bn 112.09 Bn
9 Gsk 106.08 Bn 101.91 Bn 8.24 Bn 15.38 Bn
10 Nasus Pharma 31.24 Mn 31.24 Mn - 21.29 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 21.29 Mn
Jun 30, 2025 9.58 Mn
Dec 31, 2024 -12.66 Mn